0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Erythrokinetics in the Treatment of Aplastic Anemia With Methandrostenolone

César Reynafarje, MD; José Faura
Arch Intern Med. 1967;120(6):654-660. doi:10.1001/archinte.1967.00300050010002.
Text Size: A A A
Published online

THE observation that palliative treatment of mammary gland cancer with androgens produced an increase in the number of red blood cells (RBC) in many patients has been the starting point for using these hormones in the treatment of refractory anemias. Formerly, the only treatment had been transfusions and antibiotics in order to prolong the patient's life; however, with the introduction of androgens in the treatment regime, the prognosis is being changed.1-6 At the beginning, the success was infrequent, probably because of inadequate doses, but with the use of androgens of less virilizing effects which allow larger doses, the remissions became more frequent.7-9

We have had the opportunity to treat five cases of refractory anemia with an androgen (methandrostenolone) which up to now has been used as an anabolic agent. We have studied the routine hematological indices and the erythropoietic dynamics throughout the total therapy program, allowing us to

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();